Tyme Inc. (TYME) Misses Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
TYME Announces Fourth Quarter and Fiscal Year 2020 Financial and Operating Results
May 20, 2020 4:05 PM EDTTYME-88-Panc pivotal trial enrolling patients using oral SM-88 as a potential treatment for third-line pancreatic cancer PanCAN enrolling patients in its Precision PromiseSM adaptive randomized Phase II/III registration-intent trial evaluating oral SM-88 as second-line monotherapy for pancreatic cancer TYME & Joseph Ahmed Foundations HopES sarcoma study enrolling patients for the investigator-initiated Phase II trial studying oral SM-88 as maintenance monotherapy in previously treated metastatic Ewings sarcoma and salvage monotherapy in clinically advanced sarcomas TYME to present updated findings from preclinical data on cancer metabolism-based compounds: SM-88 and TYME-18 Strategic... More
